VALENCIA, Calif., March 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that Henry L. Nordhoff has been appointed to
the board of directors of MannKind Corporation and to the board's Compensation
Committee. Mr. Nordhoff's addition brings the board of directors to a total
of nine members.
"Hank's extensive industry experience and insights will serve us very well
as we continue the development activities of MannKind," said Alfred E. Mann,
MannKind's CEO and Chairman. "We will also benefit from Hank's extensive
network as we evolve our technologies and assess new strategic opportunities
for our company."
Since July 1994, Henry Nordhoff has served as President and Chief
Executive Officer of Gen-Probe Incorporated. Prior to that, he was President
and Chief Executive Officer of TargeTech, Inc., a gene therapy company that
was merged into the Immune Response Corporation. Most of Mr. Nordhoff's
earlier career was spent at Pfizer, Inc. in senior positions in Brussels,
Seoul, Tokyo and New York. He received a B.A. in international relations and
political economy from Johns Hopkins University and an M.B.A. from Columbia
University.
About MannKind Corporation
MannKind focuses on the discovery, development and commercialization of
therapeutic products for diseases such as diabetes and cancer. The Company
recently commenced Phase 3 clinical trials in Europe of its lead product, the
Technosphere(R) Insulin System, to study its potential for the treatment of
diabetes. This System consists of a proprietary dry powder Technosphere(R)
formulation of insulin that is inhaled into the deep lung using the Company's
MedTone(TM) inhaler. MannKind believes that the performance characteristics,
unique kinetics, convenience and ease of use of the Technosphere(R) Insulin
System may have the potential to change the way diabetes is treated. For more
information on MannKind Corporation and its technology, visit
www.mannkindcorp.com.
SOURCE MannKind Corporation
Hakan Edstrom, Chief Operating Officer of MannKind Corporation, +1-661-775-5300,
hedstrom@mannkindcorp.com
